However, the findings that the apical domain of CCT1(α) is sufficient to modulate aggregation and is able to cross the plasma membrane (Sontag et al., 2013) greatly augments the potential of using CCT-mediated therapies for targeting protein misfolding diseases. The gene discussed is FLVCR2; the disease is proteostasis deficiencies.